Results 181 to 190 of about 3,754,271 (315)

A Comparison between Emergency Abdominal Surgery and Elective Abdominal Surgery in Patients Over 80 Years of Age

, 2005
Yutaka Yamazaki, Atsushi Saitô, Hiromu Takahashi   +2 more
openalex   +2 more sources

SP729KIDNEYS FROM DECEASED DONORS AGED OVER 80 YEARS ARE USEFUL FOR KIDNEY TRANSPLANTATION [PDF]

, 2017
Julio Pascual, Emma Arcos, Jordi Comas, María José Pérez‐Sáez   +3 more
openalex   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

The Stentless Freestyle Bioprosthesis: Impact of Age Over 80 Years on Quality of Life, Perioperative, and Mid-Term Outcome

, 2006
Jurgen Ennker, F Dalladaku, Ulrich Rosendahl, I. C. Ennker, M. Mauser, Ines Florath   +5 more
openalex   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias, Ana Oitabén, Sonia Zumalave, Bernardo Rodriguez‐Martin, María Gallardo‐Gómez, Martín Santamarina, Ana Pequeño‐Valtierra, Laura Juaneda‐Magdalena, Ramón García‐Escudero, José Luis López‐Cedrún, Máximo Fraga, José M. C. Tubio, Mónica Martínez‐Fernández   +12 more
wiley   +1 more source

Treatment outcomes in head and neck cancer patients aged 80 or over

, 2008
Mikio Suzuki, Sen Matayoshi, Masahiro Hasegawa, Akihiko Shinhama, Hitoshi Hirakawa, Asanori Kyuuna   +5 more
openalex   +2 more sources

Study protocol: a randomised controlled trial on the clinical effects of levothyroxine treatment for subclinical hypothyroidism in people aged 80 years and over [PDF]

, 2018
Robert S. Du Puy, Iris Postmus, David J. Stott, Manuel R. Blum, Rosalinde K.E. Poortvliet, Wendy P. J. den Elzen, Robin P. Peeters, Barbara C. Van Munster, Bruce H. R. Wolffenbuttel, Rudi G. J. Westendorp, Patricia M. Kearney, Ian Ford, Sharon Kean, Claudia‐Martina Messow, Torquil Watt, J. Wouter Jukema, Olaf M. Dekkers, Johannes W. A. Smit, Nicolas Rodondi, Jacobijn Gussekloo, Simon P. Mooijaart   +20 more
openalex   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Selection of intensive care unit admission criteria for patients aged 80 years and over and compliance of emergency and intensive care unit physicians with the selected criteria: An observational, multicenter, prospective study: Erratum

, 2009

openalex   +1 more source

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source